article thumbnail

Life Science Trends for 2023 – Xtalks Life Science Podcast Ep. 91

XTalks

In this episode, Ayesha talked about some of the trends to look out for in the life sciences in 2023. Also hear about the issue of drug shortages and how pharma companies hope to tackle it in 2023. Read the full article here: 4 Life Sciences Trends for 2023.

article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

4 Life Sciences Trends for 2023

XTalks

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

article thumbnail

World’s Top 10 Pharma Companies (By 2023 Revenue)

XTalks

The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharma companies in 2024 based on 2023 revenue.

article thumbnail

UK’s NHS Backs World’s Costliest Drug for Treatment of MLD + Report Finds Increase in Pharma Cybersecurity Threats – Xtalks Life Science Podcast Ep. 48

XTalks

In this episode, Ayesha discussed the NHS’s recommendation of Libmeldy, a gene therapy for the treatment of the rare disease MLD, which is officially the world’s most expensive drug with a list price of almost $4 million USD. New Report Finds Whopping Increase in Pharma Cybersecurity Threats.

article thumbnail

Changing Faces: agency, consultant, and investor hires from November 2022

pharmaphorum

Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. November saw the launch of a new private equity team in life sciences at J.P. Morgan Asset Management, dubbed Life Sciences Private Capital. New CEO joins UBC.

article thumbnail

After 2022 interest rate hikes spook investors, pharma M&A to resurge in late 2023

Pharmaceutical Technology

Pharma company merger and acquisition (M&A) activity in the first half of 2023 has remained relatively low, consistent with the second half of last year, but investors predict deals will increase later in 2023. Experts at PWC, Goldman Sachs, and Morgan Stanley agree that pharma-related M&A is expected to pick up in 2023.